Endometriosis Market Research, 2031
The global endometriosis market was valued at $1.2 billion in 2021 and is projected to reach $3.9 billion by 2031, growing at a CAGR of 12.6% from 2022 to 2031. Endometriosis is a condition in which an endometrium-type tissue grows outside of the uterus such as ovaries, fallopian tubes, and tissue around the uterus and ovaries. Endometriosis is grouped into four types on the basis of the affected area of the pelvis or abdomen i.e., superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis and abdominal wall endometriosis. There is various treatment which includes oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, aromatase inhibitors, and NSAIDs that are used for the treatment of endometriosis.
Historical overview
The endometriosis market was analyzed qualitatively and quantitatively from 2018-2020. Most of the growth during this period was derived from Asia-Pacific owing to the increase in females that are suffering from endometriosis that require treatment, rising disposable incomes, as well as the well-established presence of domestic companies in the region.
Market dynamics
The Endometriosis Market Size has witnessed growth, owing to increase in cases of endometriosis. For instance, according to the article of the National Library of Medicine published in June 2022, endometriosis affects approximately 10% of reproductive-aged women and approximately 17 to 44% of women diagnosed with endometriosis will experience an endometrioma.
In addition, the rise in awareness regarding endometriosis and starting of new awareness project for endometriosis are another key factor that is driving the growth of Endometriosis Market Size. For instance, in august 2022, the Endometriosis Awareness Promotion Project (EAPP) was started. EAPP is a multinational and multi-center epidemiological study. On 12th March of every year, Austria hosts the full-day free programs, online congress to cater knowledge
Furthermore, the growth in funding by governments and numerous organizations for research & development (R&D) activities in endometriosis is anticipated to drive the growth of endometriosis market. Funding plays an important role in development of advanced endometriosis treatment, expansion of endometriosis research, and research & development activities for development of more advanced effective drugs. For instance, in March 2022, the U.S. federal government announced $92 million funds to National Institute of Child Health and Human Development (NICHD) and continues to provide $370 million to the Department of Defense’s Peer-Reviewed Medical Research Program (PRMRP) for endometriosis research. in 2021, Dr Rahul Gajbhiye, Clinician-Scientist at Indian Council of Medical Research (ICMR), a National Institute for Research in Reproductive Health (NIRRH) in India, has been awarded a DBT Wellcome India Alliance Clinical and Public Health Intermediate Fellowship Grant of ₹ 3,65,90,400.00 ($0.44 million) for the five-year Endometriosis Clinical and Genetic Research in India (ECGRI) project, which focuses mainly on understanding the clinical phenotypes and genetic risks associated with endometriosis in Indian women.
Furthermore, shift in focus of key players towards care of female reproductive health, and increment in number of formation of alliance for reucing burden of endometriosis drives the growth of the endometriosis market. For instance, in November 2020, seven women’s health-focused organizations include the American College of Obstetricians and Gynecologists (ACOG), the Endometriosis Association, AbbVie, HealthyWomen, the International Pelvic Pain Society (IPPS), GE Healthcare and Black Women’s Health Imperative (BWHI) announced the formation of the Alliance for Endometriosis to improve the lives of the one in 10 women of reproductive age living with this disease in the U.S.
COVID-19 outbreak is anticipated to have a negative impact on the endometriosis market. In 2020 and 2021, the outpatient department (OPD) for patients took a potential backlog and was almost close due to rapidly rising COVID-19 cases; only elective emergency cases were taken and home care was preferred more. For instance, according to a study published by BioMed Central Ltd, in 2021, a decrease of 14.8% was observed for elective procedures performed in Germany and around 6.0% decrease for emergency procedures. Moreover, the supply chain of endometriosis medicine was disrupted completely, owing to the closure of manufacturing operations and unavailability of raw metal such as gelatin. For instance, according to the Economic Times of Industry, drugmakers rely on animal bones for gelatin (a clear substance used in outer casings of the oral dosage form). And the slaughterhouse or abattoirs were closed due to lockdown. Therefore, the lockdown is to blame for this shortage, which highlights the delicate and intricate linkages in the manufacturing value chain.
However, with relaxation in lockdowns and decline in COVID-19 cases, companies have re-started their processes to meet the demand for products. The majority of the hospitals have resumed OPD, thus, an increase in the demand of endometriosis medicine is expected. In addition, rise in awareness in pharmaceutical companies, and governments regarding supply chain hinderance of pharmaceutical products drives the growth of endometriosis market.
For instance, government agencies in the U.S. and around the globe learned some tough lessons about the pharmaceutical supply chain after the COVID-19 pandemic landed, causing problems and highlighting weaknesses in key areas. In the session of "U.S. Government Investments in Pharmaceutical Manufacturing and Supply Chain for Today's and Future Pandemics" at the 2022 BIO International Conference, representatives from U.S. health agencies shared lessons learned from COVID-19, and how government and industry are collaborating to avoid future supply chain crises. In addition, the U.S. leaders stated that the government has learned since the beginning of the pandemic, steps taken since COVID-19's arrival, and plans the U.S. has put in place to avoid problems in the future.
Furthermore, increase in initiative taken by government, surge in funding for endometriosis research, rise in key strategy adopted by key players such as product approval is expected to witness growth of endometriosis market during the forecast period. For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need. Thus, such trends are expected to bring stabilization in the market, and subsequently witness growth rate during the forecast period.
The endometriosis market is segmented into Type, Distribution channel and Treatment.
Segmental Overview
The endometriosis market is segmented on the basis of type, treatment, distribution channel, and region. On the basis of type, the market is classified into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). On the basis of treatment, the market is classified into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. Depending on the distribution channel, it is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Type
The endometriosis market is segmented into superficial peritoneal endometriosis, endometriomas, and others (deeply infiltrating endometriosis, abdominal wall endometriosis). the superficial peritoneal lesion segment generated maximum Endometriosis Market Share in 2021 and is also expected to witness highest CAGR during the forecast period, owing to increase in prevalence of superficial peritoneal lesion, and development of programs to increase in awareness regarding endometriosis. In addition, an increase in funding from government regarding endometriosis research has propelled the growth of superficial peritoneal lesion segment.
By Treatment
The oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, and others. The oral contraceptives segment generated maximum revenue in 2021, owing to high adoption of oral contraceptives, and increase in cases of menstrual problem. The gonadotropin-releasing hormone (GnRH) medicines is expected to witness highest CAGR during the forecast period, owing to rise in number of endometriosis cases and rise in awareness regarding use of gonadotropin-releasing hormone (GnRH) medicines for the treatment of endometriosis.
By End User
The endometriosis market is classified into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment was the highest revenue contributor to the market in 2021, owing to surge in number of hospital pharmacies, and increase in patient’s trust in hospitals as they have high-quality services. The online pharmacy is expected to witness the highest CAGR during the forecast period, owing to more convenience, fewer expenses, easy access to patient reviews, and price comparisons facility.
By Region
The endometriosis market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major share of the endometriosis market in 2021 and is expected to maintain its dominance during the forecast period. The presence of several major players, such as Abbott Laboratories, Merck & Co. Inc., and Pfizer Inc. and advancement in manufacturing technology of medicines in the region drive the growth of the market. This is majorly attributed to surge in incidences of endometriosis which further require treatment such as gonadotropin-releasing hormone (GnRH) medicines, rise in funding from government for research regarding treatment of endometriosis and significant rise in capital income in developed countries. Furthermore, the existence of sophisticated reimbursement structure that aims to reduce expenditure levels, drives the growth of the market. Hence, such factors propel market growth. In addition, the U.S. is anticipated to contribute to a major share of the regional market and is expected to drive growth of the endometriosis market throughout the forecast period. The presence of well-established healthcare infrastructure, high purchasing power, and rise in adoption rate of endometriosis medicine are expected to drive the market growth.
Asia-Pacific is expected to grow at the highest rate during the endometriosis market forecast period. The endometriosis market growth in this region is attributable to rise in number of endometriosis in this region as well as growth in the purchasing power of populated countries, such as China and India. The countries in Asia-Pacific possess a huge population base, with China being the first having 1,397,715 population in 2020 and India is the second most populated countries having 1,366,417.75 population in 2020.
COMPETITION ANALYSIS
Competitive analysis and profiles of the major players in the Endometriosis Industry, such as Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Consilient Health Limited, GlaxoSmithKline plc, Merck & Co. Inc, Pfizer Inc, Sanofi India Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Ltd. are provided in this report. There are some important players in the market such as GlaxoSmithKline plc, and Pfizer Inc have adopted product approval, as key developmental strategies to improve the product portfolio of the patient blood management market.
Some examples of product approval in the market
In March 2020, GlaxoSmithKline, a world leader in pain relief, received approval from the U.S. Food and Drug Administration (FDA) for Advil Dual Action. It is a OTC combination of ibuprofen and acetaminophen for pain relief.
In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant’s commitment to women’s health in areas of significant unmet need.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the endometriosis market analysis from 2021 to 2031 to identify the prevailing Endometriosis Market Opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the endometriosis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global endometriosis market trends, key players, market segments, application areas, and market growth strategies.
Endometriosis Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 3.9 billion |
 Growth Rate | CAGR of 12.6% |
 Forecast period | 2021 - 2031 |
 Report Pages | 220 |
 By Type |
|
 By Distribution channel |
|
 By Treatment |
|
 By Region |
|
 Key Market Players | Abbvie Inc, AstraZeneca plc, Teva Pharmaceutical Industries Limited, Consilient Health Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Torrent Pharmaceuticals Ltd, Merck & Co. Inc., Sanofi, Abbott Laboratories, Serum Institute of India Pvt. Ltd. |
Analyst Review
The endometriosis market has witnessed growth, owing to high prevalence of endometriosis and availability of various medicine such as gonadotropin-releasing hormone agonist, and birth control pill.
Moreover, the rise in demand for novel drugs and hormonal therapies, rise in awareness regarding early disease diagnosis and treatment of endometriosis among global population propel the growth of endometriosis market. Furthermore, the increase in demand for gonadotropin-releasing hormone agonist for the management of endometriosis, rise in key strategies adopted by key players boosts the growth of the market. Rise in R&D activities for advanced endometriosis treatments and increase in funding from government for research drives the growth of endometriosis market during the forecast period.
North America is expected to witness the highest growth, in terms of revenue, owing to an increase in cases of endometriosis, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to an increase in awareness related reproductive health, endometriosis, unmet medical demands, high population base and increase in public–private investments in the healthcare sector.
The total market value of the Endometriosis Market is $1239.81 million in 2021.
The forecast period in the report is from 2022 to 2031.
The market value of the Endometriosis Market in 2022 was $1346.43 million.
North America is the largest regional market for Endometriosis.
Abbott Laboratories, Consilient Health Limited, GlaxoSmithKline plc, Merck & Co. Inc, Pfizer Inc, Sanofi India Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Ltd.
The base year for the report is 2021.
Yes, Endometriosis companies are profiled in the report.
The key trends in the Endometriosis Market are increasing prevalence of endometriosis, and a surge in technological advancement in endometriosis treatment.
Loading Table Of Content...
